

# in vivo

International Journal of Experimental and Clinical Pathophysiology and Drug Research

Volume 34, Number 1, January-February 2020

## Contents

### Reviews

- Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. C. HOLZMANN, W. KUEPKER, B. ROMMEL, B. HELMKE, J. BULLERDIEK (*Rostock; Baden Baden-Buehl; Bremen; Stade, Germany*) ..... 1
- Three-dimensional Versus Two-dimensional Laparoscopic Surgery for Colorectal Cancer: Systematic Review and Meta-analysis. G. PANTALOS, D. PATSOURAS, E. SPARTALIS, D. DIMITROULIS, G. TSOUROUFLIS, N. NIKITEAS (*Athens, Greece*) ..... 11
- Intraoperative Indocyanine Green (ICG) Angiography for the Identification of the Parathyroid Glands: Current Evidence and Future Perspectives. E. SPARTALIS, G. NTOKOS, K. GEORGIU, G. ZOGRAFOS, G. TSOUROUFLIS, D. DIMITROULIS, N.I. NIKITEAS (*Athens, Greece*) ..... 23

### Experimental Studies

- Fanconi Anemia Mouse Genotype-specific Mitigation of Total Body Irradiation by GS-Nitroxide JP4-039. M.W. EPPERLY, R. FISHER, X. ZHANG, W. HOU, D. SHIELDS, P. WIPF, H. WANG, S. THERMOZIER, J.S. GREENBERGER (*Pittsburgh, PA, USA*)..... 33
- Second-generation Probiotics Producing IL-22 Increase Survival of Mice After Total Body Irradiation. X. ZHANG, R. FISHER, W. HOU, D. SHIELDS, M.W. EPPERLY, H. WANG, L. WEI, B.J. LEIBOWITZ, J. YU, L.M. ALEXANDER, J.-P. VAN PIJKEREN, S. WATKINS, P. WIPF, J.S. GREENBERGER (*Pittsburgh, PA; Madison, WI, USA*) ..... 39
- The Association of *MMP7* Genotype With Pterygium. P.-S. HU, Y.-C. WANG, C.-H. LIAO, N.-Y. HSIA, M.-F. WU, J.-S. YANG, C.-C. YU, W.-S. CHANG, D.-T. BAU, C.-W. TSAI (*Taichung; Changhua; Taipei, Taiwan, ROC*)..... 51

Contents continued on the back cover

# in vivo

International Journal of Experimental and Clinical Pathophysiology and Drug Research



ISSN (print): 0258-851X, ISSN (online): 1791-7549

## Editorial Board

- I. ABRAHAM, Tucson, AZ, USA  
N. J. AGNANTIS, Ioannina, Greece  
D. ANDERSON, Bradford, West Yorkshire, UK  
V. BARAK, Jerusalem, Israel  
M. H. BARCELLOS-HOFF, New York, NY, USA  
K. BEIER, Basel, Switzerland  
M. BERGQVIST, Uppsala, Sweden  
R. BJERKVIG, Bergen, Norway  
W. BOWNE, Philadelphia, PA, USA  
M. CARAGLIA, Naples, Italy  
P. CHANDRA, Frankfurt am Main, Germany  
J.-G. CHUNG, Taichung, Taiwan, ROC  
L. A. COHEN, Northampton, MA, USA  
A. I. CONSTANTINOU, Nicosia, Cyprus  
T. DALIANIS, Stockholm, Sweden  
D. T. DENHARDT, Bridgewater, NJ, USA  
W. DEN OTTER, Amsterdam, The Netherlands  
K. DE MEIRLEIR, Brussels, Belgium  
L. DE RIDDER, Ghent, Belgium  
E. P. DIAMANDIS, Toronto, ON, Canada  
J.M. DRAKE, New Brunswick, NJ, USA  
T. EFFERTH, Mainz, Germany  
W. ENGSTRÖM, Uppsala, Sweden  
M. ESKELINEN, Kuopio, Finland  
J. A. FERNANDEZ-POL, Chesterfield, MO, USA  
G. FIORENTINI, Pesaro, Italy  
P. B. FISHER, New York, NY, USA  
I. FREITAS, Pavia, Italy  
M. FRIEDRICH, Krefeld, Germany  
R. E. FRIEDRICH, Hamburg, Germany  
R. GANAPATHI, Charlotte, NC, USA  
G. GITSCH, Freiburg, Germany  
V. GORGOLIS, Athens, Greece  
J. S. GREENBERGER, Pittsburgh, PA, USA  
J. W. GREINER, Bethesda, MD, USA  
C. J. GRUBBS, Birmingham, AL, USA  
F. GUADAGNI, Rome, Italy  
J. HAU, Copenhagen, Denmark  
M. HAUER-JENSEN, Little Rock, AR, USA  
K. HIBI, Kakamigahara, Japan  
S. A. IMAM, Pasadena, CA, USA  
K. S. JEONG, Daegu, S. Korea  
M. JHANWAR-UNIYAL, Valhalla, NY, USA  
I. KISS, Pécs, Hungary  
E. KONDO, Niigata, Japan  
M. KOUTSILIERIS, Athens, Greece  
G. R. F. KRUEGER, Köln, Germany  
N. KYPRIANOU, Lexington, KY, USA  
S. A. LAMPRECHT, New York, NY, USA  
G. LANDBERG, Lund, Sweden  
I. LELONG-REBEL, Illkirch, France  
J. LEROY, Strasbourg, France  
W. LICHTENEGGER, Berlin, Germany  
J. LYKKESFELDT, Frederiksberg, Denmark  
P. MADARNAS, Sherbrooke, QC, Canada  
H. MAEDA, Kumamoto, Japan  
M. MAREEL, Ghent, Belgium  
L. MARGOLIS, Bethesda, MD, USA  
G. MARTORANA, Bologna, Italy  
J. MOLNÁR, Szeged, Hungary  
S.L. MOOBERRY, San Antonio, TX, USA  
N. MOTOHASHI, Tokyo, Japan  
R. M. NAGLER, Haifa, Israel  
S. NAKANO, Fukuoka, Japan  
M. NAKASHIMA, Nagasaki, Japan  
R. NARAYANAN, Boca Raton, FL, USA  
M.B. NICHOLL, San Antonio, TX, USA  
K. NILSSON, Uppsala, Sweden  
K. R. NORUM, Oslo, Norway  
K. OGAWA, Tokyo, Japan  
M. PAGÉ, Laval, QC, Canada  
C. POLYCHRONAKOS, Montreal, QC, Canada  
M.-F. POUPON, Paris, France  
D. RADES, Liibeck, Germany  
F. M. ROBERTSON, Richmond, VA, USA  
D. RUBELLO, Rovigo, Italy  
C. A. RUBIO, Stockholm, Sweden  
G. R. RUTTEMAN, Utrecht, The Netherlands  
H. SAKAGAMI, Saitama, Japan  
G. SAVA, Trieste, Italy  
D. SCHIFFER, Vercelli, Italy  
L. D. SHULTZ, Bar Harbor, ME, USA  
G. SICA, Rome, Italy  
J. SIEGFRIED, Minneapolis, MN, USA  
J. SLANSKY, Denver, CO, USA  
R. M. SNAPKA, Columbus, OH, USA  
G.-I. SOMA, Kagawa, Japan  
P. P. SORDILLO, New York, NY, USA  
T. A. SPRINGER, Boston, MA, USA  
D. D. SPYROPOULOS, Charleston, SC, USA  
K. SYRJÄNEN, Helsinki, Finland  
G. C. TORRE, Finale Ligure (SV), Italy  
B. TRIBUKAIT, Stockholm, Sweden  
J. VADGAMA, Los Angeles, CA, USA  
J.K. VISHWANATHA, Fort Worth, TX, USA  
W. WANG, Wolverhampton, UK  
N. WATANABE, Sapporo, Japan  
W. WEBER, Basel, Switzerland  
L. M. WEINER, Washington, DC, USA  
J. A. WERNER, Marburg, Germany  
S. YLÄ-HERTTUALA, Kuopio, Finland  
H. YOSHIDA, Kagoshima, Japan

G. J. DELINASIOS, Athens, Greece  
Managing Editor and Executive Publisher

Editorial Office: journals@iiar-anticancer.org  
Managing Editor: editor@iiar-anticancer.org

For more information about IN VIVO, IJAR and the International Conferences of Anticancer Research, please visit the IJAR website: www.iiar-anticancer.org

J. G. DELINASIOS, Athens, Greece  
Managing Editor and Executive Publisher  
(1987-2016)

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ, 07732, USA. e-mail: journals@iiar-anticancer.org.

**General Policy:** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis; 10. Retrospective studies and case reports.

IN VIVO supports: (a) the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research (www.iiar-anticancer.org).

**Publication Data:** IN VIVO is published bimonthly online-only and open access by the International Institute of Anticancer Research. Each annual volume comprises six issues. Annual Author and Subject Indexes are included in the sixth issue of each volume. IN VIVO Vol. 18 (2004) and onwards appears online with Stanford University HighWire Press. All published articles are deposited in PubMed Central.

**Copyright:** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and HTML files of all articles published in IN VIVO are the property of the publisher.

**Open Access Policy:** Open Access Policy: IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to contribute an online publication fee of US\$ 700 for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged US\$ 60,00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume, issue, and page numbering.

Articles in IN VIVO are regularly indexed in bibliographic services, including Index Medicus, PubMed, MEDLINE, Biological Abstracts, Chemical Abstracts, Biosis Previews, Science Citation Index Expanded, Essential Science Indicators, Chemical Abstracts, Excerpta Medica, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, CANCER-LIT Database, University of Sheffield Biomedical Information Service (SUBIS), Current Clinical Cancer, AIDS Abstracts, Progress in Palliative Care, Update-Research Information Systems Inc., Inpharma-Reactions Datastar, BRS, Reference Update (I.S.I.), Research Alert, Science Citation Index Expanded, Biochemistry & Biophysics Citation (I.S.I.), BioBase, MedBase, Google Scholar, Investigational Drugs Database, VINI Abstracts Journal, PubsHub, SIIC Data Bases.

The Editors and Publishers of IN VIVO accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

**All correspondence** status of submitted manuscripts, change of address, general editorial matters, advertising rate requests) should be addressed to the Editorial Office, e-mail: journals@iiar-anticancer.org. Articles should be submitted only through our online submission system (www.iiar-submissions.com).

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

# **in vivo**

**International Journal of Experimental and  
Clinical Pathophysiology and Drug Research**

ISSN (print): 0258-851X; ISSN (online): 1791-7549

**Volume 34  
2020**

## Editorial Board

- I. ABRAHAM, *The HOPE Center, University of Arizona, Tucson, AZ, USA*
- N.J. AGNANTIS, *Department of Pathology, University of Ioannina, Ioannina, Greece*
- D. ANDERSON, *Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK*
- V. BARAK, *Department of Oncology, Hadassah University Hospital, Jerusalem, Israel*
- M.H. BARCELLOS-HOFF, *Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA*
- K. BEIER, *Department of Histology, University of Basel, Basel, Switzerland*
- M. BERGQVIST, *Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala, Sweden*
- R. BJERKVIG, *Norlux Neuro-Oncology, Department of Biomedicine, University of Bergen, Bergen, Norway*
- W. BOWNE, *Department of Surgery, Drexel University College of Medicine, Philadelphia, PA, USA*
- M. CARAGLIA, *Department of Experimental Oncology, National Institute of Tumours Fondazione G. Pascale, Naples, Italy*
- P. CHANDRA, *Department of Molecular Biology, Frankfurt University, Frankfurt am Main, Germany*
- J.-G. CHUNG, *Department of Medicine, China Medical College, Taichung, Taiwan, ROC*
- L.A. COHEN, *Northampton, MA, USA*
- A.I. CONSTANTINOU, *Department of Biological Sciences, University of Cyprus, Nicosia, Cyprus*
- T. DALIANIS, *Department of Pathology-Oncology, Karolinska Institute, Stockholm, Sweden*
- D.T. DENHARDT, *Division of Life Sciences, Rutgers University, Bridgewater, NJ, USA*
- W. DEN OTTER, *VUMC - Department of Urology, Amsterdam, The Netherlands*
- K. DE MEIRLEIR, *Department of Human Physiology and Medicine, Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium*
- L. DE RIDDER, *Department of Anatomy, Embryology and Histology, University of Ghent, Ghent, Belgium*
- E.P. DIAMANDIS, *Department of Pathology and Laboratory Medicine, University of Toronto, Toronto, Ontario, Canada*
- J.M. DRAKE, *Division of Medical Oncology, RBHS-Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA*
- T. EFFERTH, *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Germany*
- W. ENGSTRÖM, *Department of Molecular Biosciences, Swedish University of Agricultural Sciences, Uppsala, Sweden*
- M. ESKELINEN, *Department of Surgery, University Hospital of Kuopio, Kuopio, Finland*
- J.A. FERNANDEZ-POL, *Metalloproteomics, LLC, Chesterfield, MO, USA*
- G. FIORENTINI, *UOC Oncologia, Azienda Ospedaliera Marche Nord, Pesaro, Italy*
- P.B. FISHER, *Virginia Commonwealth University, School of Medicine, Richmond, VA, USA*
- I. FREITAS, *Dipartimento di Biologia Animale, University of Pavia, Pavia, Italy*
- M. FRIEDRICH, *Department of Obstetrics and Gynecology, Klinikum Krefeld, Krefeld, Germany*
- R.E. FRIEDRICH, *Department of Oral and Maxillofacial Surgery, Eppendorf University Hospital, Hamburg, Germany*
- R. GANAPATHI, *Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA*
- G. GITSCH, *Department of Gynecology and Obstetrics, University of Freiburg Medical Center, Freiburg, Germany*
- V. GORGOLIS, *Department of Histology-Embryology, Medical School, University of Athens, Greece*
- J.S. GREENBERGER, *Department of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA*
- J.W. GREINER, *National Cancer Institute, NIH, Bethesda, MD, USA*
- D.S. GRIDLEY, *Department of Radiation Medicine, Radiation Research Laboratories, Loma Linda University and Medical Center, Loma Linda, CA, USA*
- C.J. GRUBBS, *Department of Nutrition Sciences, University of Alabama, Birmingham, AL, USA*
- F. GUADAGNI, *IRCCS San Raffaele, Rome, Italy*

- J. HAU**, *Department of Comparative Medicine, University of Copenhagen, Denmark*
- M. HAUER-JENSEN**, *Arkansas Cancer Research Center, University of Arkansas Medical Sciences, Little Rock, AR, USA*
- K. HIBI**, *Tokai Central Hospital, Kakamigahara, Gifu, Japan*
- S.A. IMAM**, *Huntington Medical Research Institutes, Gene Therapy Program, Pasadena, CA, USA*
- K.S. JEONG**, *Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, S. Korea*
- M. JHANWAR-UNIYAL**, *Department of Neurosurgery, New York Medical College, Valhalla, NY, USA*
- I. KISS**, *Institute of Preventive Medicine, Medical School, University of Pécs, Pécs, Hungary*
- E. KONDO**, *Division of Molecular and Cellular Pathology Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan*
- M. KOUTSILIERIS**, *Department of Experimental Physiology, University of Athens Medical School, Athens, Greece*
- G.R.F. KRUEGER**, *Department of Anatomy II, Center for Anatomy, The University of Cologne Medical School, Cologne, Germany*
- B. KRUSLIN**, *Department of Pathology, Ljudevit Jurak University, Sestre milosrdnice University Hospital, Zagreb, Croatia*
- N. KYPRIANOU**, *Department of Urology, University of Kentucky, Lexington, KY, USA*
- G. LANDBERG**, *Department of Laboratory Medicine, Lund University, Lund, Sweden*
- I. LELONG-REBEL**, *Lab. de Biophotonique et Pharmacologie, Université de Strasbourg, Illkirch, France*
- J. LEROY**, *IRCAD, University of Strasbourg, France*
- W. LICHTENEGGER**, *Charité Campus Virchow-Klinikum, Berlin, Germany*
- J. LYKKESFELDT**, *Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark*
- P. MADARNAS**, *Department of Pathology, University of Sherbrooke, Québec, Canada*
- H. MAEDA**, *BioDynamics Research Foundation, Kumamoto, Japan*
- M. MAREEL**, *Laboratory of Experimental Cancerology, State University, Ghent, Belgium*
- L. MARGOLIS**, *Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA*
- G. MARTORANA**, *Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy*
- J. MOLNÁR**, *Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary*
- S.L. MOOBERRY**, *Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA*
- N. MOTOHASHI**, *Department of Medicinal Chemistry, Meiji Pharmaceutical University, Tokyo, Japan*
- R.M. NAGLER**, *Department of Oral and Maxillofacial Surgery, Rambam Medical Center, Haifa, Israel*
- S. NAKANO**, *Graduate School of Health and Nutritional Sciences, Nakamura Gakuen University, Fukuoka, Japan*
- M. NAKASHIMA**, *Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan*
- R. NARAYANAN**, *Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA*
- M.B. NICHOLL**, *South Texas Veterans Health Care System, San Antonio, TX, USA*
- K. NILSSON**, *Tumor Biology Laboratory, Department of Pathology, University Hospital, Uppsala, Sweden*
- K.R. NORUM**, *Institute for Nutrition Research, University of Oslo, Oslo, Norway*
- K. OGAWA**, *Department of Surgery, Tokyo Women's Medical University Medical Center East, Tokyo, Japan*
- M. PAGÉ**, *Département de Biologie, Division de Biochimie, Université Laval, Québec, Canada*
- C. POLYCHRONAKOS**, *Department of Paediatrics and Human Genetics, McGill University Health Centre Research Institute, Montreal, QC, Canada*
- M.-F. POUPON**, *Institut Curie, Section de Recherche, Paris, France*
- D. RADES**, *Department of Radiation Oncology, University of Lübeck, Lübeck, Germany*
- F.M. ROBERTSON**, *Virginia Commonwealth University, Clinical Research Services, Center for Clinical and Translational Research, Richmond Academy of Medicine, Richmond, VA, USA*

*continued*

- D. RUBELLO, *Department of Nuclear Medicine, PET Unit, S. Maria della Misericordia Hospital, IOV, Rovigo, Italy*
- C.A. RUBIO, *Karolinska Institute, Pathology Research Laboratory, Stockholm, Sweden*
- G.R. RUTTEMAN, *Department of Clinical Sciences of Companion Animals, University of Utrecht, Utrecht, The Netherlands*
- H. SAKAGAMI, *Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan*
- G. SAVA, *Institutes of Biological Research, Fondazione Callerio-Onlus, Trieste, Italy*
- D. SCHIFFER, *Neuro-bio-oncology Center, Policlinico di Monza Foundation, University of Turin, Vercelli, Italy*
- L.D. SHULTZ, *The Jackson Laboratory, Bar Harbor, ME, USA*
- G. SICA, *Istituto di Istologia ed Embriologia, Universita Cattolica del Sacro Cuore, Roma, Italy*
- J.M. SIEGFRIED, *Department of Pharmacology, MNPI Center, University of Minnesota, Minneapolis, MN, USA*
- J. SLANSKY, *Integrated Department of Immunology, School of Medicine, University of Colorado Denver and National Jewish Health, Denver, CO, USA*
- R.M. SNAPKA, *Department of Radiology, The Ohio State University, Columbus, OH, USA*
- G.-I. SOMA, *Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan*
- P.P. SORDILLO, *Department of Medical Oncology and Hematology, Lenox Hill Hospital, New York, NY, USA*
- T.A. SPRINGER, *Department of Pathology, Harvard Medical School, Boston, MA, USA*
- D.D. SPYROPOULOS, *Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, USA*
- K. SYRJÄNEN, *Biohit Healthcare Oyj, Helsinki, Finland*
- G.C. TORRE, *Centro Ippocrate, Vico Cosmelli 4, Finale Ligure (SV), Italy*
- B. TRIBUKAIT, *Department of Medical Radiobiology, Karolinska Hospital, Stockholm, Sweden*
- J. VADGAMA, *Department of Internal Medicine, Charles E. Drew University of Medicine and Science, Los Angeles, CA, USA*
- J.K. VISHWANATHA, *Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA*
- W. WANG, *Research Institute of Healthcare Science, University of Wolverhampton, Wolverhampton, UK*
- N. WATANABE, *Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan*
- W. WEBER, *Clinical Cancer Etiology Unit, Basel, Switzerland*
- L.M. WEINER, *Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA*
- J.A. WERNER, *Department of Otolaryngology, Head and Neck Surgery, Marburg, Germany*
- S. YLÄ-HERTTUALA, *Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland*
- H. YOSHIDA, *Department of Pathology, Kagoshima University, Kagoshima, Japan*

## Acknowledgements

The following Organisations supported many of the works published in IN VIVO, Volume 33, 2019.

2017 Young Medical Science Researcher Grants, Ewha Womans University College of Medicine, Seoul, Republic of Korea

90th Anniversary of Chulalongkorn University Fund, Chulalongkorn University, Bangkok, Thailand

Academia Sinica, Taipei City, Taiwan, R.O.C.

Ajou University Medical Center, Suwon, Republic of Korea

AO Foundation, Davos, Switzerland

Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea

AstraZeneca plc, Cambridge, U.K.

Australia Awards PhD Scholarship, Department of Foreign Affairs and Trade, Barton, Australia

Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT, Gwacheon, Republic of Korea

BEGO Implant Systems GmbH & Co. KG, Bremen, Germany

Bio & Medical Technology Development Program, National Research Foundation of Korea (NRF), Ministry of Science and ICT, Gwacheon, Republic of Korea

Biosignature Project and Biomarker Project, Academia Sinica, Taipei, Taiwan, R.O.C.

Breast Cancer Hope Foundation, London, U.K.

Chang Bing Show Chwan Memorial Hospital, Lukang, Taiwan, R.O.C.

Chang Gung Memorial Foundation, Taipei City, Taiwan, R.O.C.

Cheng-Hsin General Hospital, Taipei City, Taiwan, R.O.C.

China Medical University Beigang Hospital, Beigang, Taiwan, R.O.C.

China Medical University Hospital, Taichung, Taiwan, R.O.C.

China Medical University, Taichung, Taiwan, R.O.C.

China Scholarship Council (CSC) Grant, Ministry of Education of the People's Republic of China, Beijing, P.R. China

Chonnam National University Hospital Biomedical Research Institute, Gwangju, Republic of Korea

Chosun University Research Aid Scholarship Program, Gwangju, Republic of Korea

Chugai Co., Ltd., Tokyo, Japan

Chulalongkorn University, Bangkok, Thailand

Consejo Nacional De Ciencia y Tecnología (CONACYT), México, Mexico

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, Brazil

Czech University of Life Sciences, Prague, Czech Republic

Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, R.O.C.

Dental Research Center, Nihon University School of Dentistry, Tokyo, Japan

Department of Life Science, Gachon University, Seongnam, Republic of Korea

Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan

Department of Molecular and Cellular Biology, Wrocław Medical University, Wrocław, Poland

Department of Molecular Cell Biology and Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA, U.S.A.

Department of Pathology, Lake Erie College of Osteopathic Medicine, Erie, PA, U.S.A.

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan

Division of Hematology, Barnes-Jewish Hospital, St. Louis, MO, U.S.A.

Endowment Fund, Chulalongkorn University, Bangkok, Thailand

Executive Unit for Financing Higher Education, Research, Development and Innovation (UEFISCDI), Romania  
Experimental Research Center of 'ELPEN', Pikermi, Greece

Faculty of Dentistry, University of Barcelona, Barcelona, Spain

Faculty of Dentistry, University of La Frontera, Temuco, Chile  
Faxitron, Tucson, AZ, U.S.A.

Finnish Medical Association, Helsinki, Finland

Flinders Medical Centre Foundation Seeding Grant, Bedford Park, Australia

Franz-Penzoldt-Zentrum, Erlangen, Germany

Fundacao Araucaria, Curitiba, Brazil

G. Pascale Foundation, National Tumor Institute, Naples, Italy  
Gastroenterological Center, Yokohama City University

Medical Center, Yokohama, Japan

Gencurix Inc., Seoul, Republic of Korea

Genentech, South San Francisco, CA, U.S.A.

Gerhard Domagk Grant, University Medicine Greifswald, Greifswald, Germany

German Federal Ministry of Education and Research, Bonn, Germany

Grant for International Research Integration: Research Pyramid, Ratchadaphiseksomphot

- Grants-in-Aid for Scientific Research (KAKENHI), Japan  
Society for the Promotion of Science, Tokyo, Japan
- Handok Inc., Seoul, Republic of Korea  
Hannover Biomedical Research School, Hannover, Germany  
Hannover Medical School, Hannover, Germany  
Heilongjiang Bayi Agricultural University, Daqing, P.R. China  
Hellenic Endocrine Society, Athens, Greece  
Hellenic Foundation for Research and Innovation (HFRI),  
Athens, Greece  
Hellenic Study Group of Psychoneuroimmunology in Cancer,  
Athens, Greece  
HFRI PhD Fellowship Grant, General Secretariat for Research  
and Technology (GSRT), Athens, Greece
- Industrial Technology Innovation Program, Ministry of  
Trade, Industry, & Energy (MOTIE), Sejong,  
Republic of Korea  
Instituto Mexicano del Seguro Social (IMSS), Mexico City,  
Mexico  
International Research Integration: Chula Research Scholar,  
Chulalongkorn University, Bangkok, Thailand  
Intramural Research Fund, Ajou University Medical Center,  
Suwon, Republic of Korea  
Istanbul University Scientific Projects Unit, Istanbul, Turkey  
Italian Ministry of Health, Rome, Italy
- Jilin Provincial Health Department Project of China, Jilin,  
P.R. China
- Kafkas University, Kars, Turkey  
Kanagawa Standard Anti-cancer Therapy Support System,  
Japan  
Klin-StrucMed Program, Else-Kröner-Foundation (Else-  
Kröner-Stiftung), Bad Homburg vor der Höhe, Germany  
Korea Health Technology R&D Project, Korea Health Industry  
Development Institute (KHIDI), Ministry of Health &  
Welfare, Seoul, Republic of Korea  
Korea Research Institute of Bioscience and Biotechnology  
(KRIBB), Daejeon, Republic of Korea  
Korean Research Institute of Bioscience and Biotechnology  
Research Initiative Program, Daejeon, Republic of Korea  
Krajska zdravotni, a.s, Ústí nad Labem, Czech Republic  
Kyungpook National University Research Fund, Daegu,  
Republic of Korea
- Leibniz-Institut für Plasmaforschung und Technologie e.v.  
(INP) Greifswald, Greifswald, Germany  
Lions Melvin Jones Eye Bank, Genoa, Italy
- Mackay Medical College, New Taipei City, Taiwan, R.O.C.  
Marie Skłodowska-Curie Grant, Horizon 2020 Research and  
Innovation Programme, European Union
- Medical Center – University of Freiburg, Freiburg im  
Breisgau, Germany  
Medical Research Core Facilities Center, Office of Research &  
Development at China Medical University, Taichung,  
Taiwan, R.O.C.  
Meikai University School of Dentistry, Sakado, Japan  
Ministry of Education and Scientific Research, Bucharest, Romania  
Ministry of Education, Culture, Sports, Science and  
Technology of Japan, Tokyo, Japan  
Ministry of Education, Youth and Sports, Prague, Czech Republic  
Ministry of Science and Higher Education, Warsaw, Poland  
Ministry of Science and Technology (MOST), Taipei, Taiwan,  
R.O.C.  
Ministry of Trade, Industry and Energy (MOTIE), Sejong City,  
Republic of Korea
- National Center for Genome Medicine (NCGM), Taipei,  
Taiwan, R.O.C.  
National Centre for Research and Development in Poland,  
Warsaw, Poland  
National Health Research Institute of Taiwan, Miaoli, Taiwan,  
R.O.C.  
National Institute of Environmental Research, Incheon,  
Republic of Korea  
National Institute of Health Sciences (NIHS), Tokyo, Japan  
National Institutes of Health (NIH), Department of Health and  
Human Services, Bethesda, MD, U.S.A.  
National R&D Program for Cancer Control,  
Ministry of Health and Welfare, Sejong, Republic of Korea  
National Science Centre (NCN), Warsaw, Poland  
Nestlé Nutrition Council Japan, Tokyo, Japan  
Next-Generation BioGreen 21 Program, Ministry of Trade,  
Industry, & Energy (MOTIE), Sejong, Republic of Korea  
Nihon University Multidisciplinary Research Grant, Nihon  
University, Tokyo, Japan  
Non-profit Organization (NPO) for Supporting Clinical  
Research, Japan  
Novartis Pharmaceuticals Corporation, Hanover, NJ, U.S.A.
- Ono Pharmaceutic Co., Ltd., Osaka, Japan  
Onuki General Foundation, Japan
- Pharmaceutical Research Instrument Center, Faculty of  
Pharmaceutical Sciences, Chulalongkorn University,  
Bangkok, Thailand  
Pirkanmaa Cancer Association, Tampere, Finland  
Polish Ministry of Science and Higher Education, Warsaw,  
Poland  
Promoted Research, Kanazawa Medical University,  
Uchinada, Japan
- Rachadapisek Sompote Fund, Chulalongkorn University,  
Bangkok, Thailand



- Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University, Bangkok, Thailand
- Research Grant, Medical University of Lublin, Lublin, Poland
- Research Grant, University of Malaya, Kuala Lumpur, Malaysia
- Research Institute of Rangsit University, Rangsit University, Mueang Pathum Thani, Thailand
- Rural Development Administration, Ministry of Trade, Industry, & Energy (MOTIE), Sejong, Republic of Korea
- Samsung Medical Center Intramural Grant, Seoul, Republic of Korea
- Sato Foundation, San Rafael, CA, U.S.A.
- Scientific Research Projects Coordination Unit, Istanbul University, Istanbul, Turkey
- Seoul National University, Seoul, Republic of Korea
- Seppo Nieminen Legacy Fund, Finland
- Signe and Ane Gyllenberg Foundation, Finland
- Silpakorn University Research and Development Institute, Bangkok, Thailand
- Statutory Funds, Department of Molecular and Cellular Biology, Wroclaw Medical University, Wroclaw, Poland
- Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan
- Support Project And R&D Company (SPARC), Korea Institute for Advancement of Technology (KIAT), Seoul, Republic of Korea
- Taipei Veterans General Hospital, Taipei City, Taiwan R.O.C.
- Taipei Veterans General Hospital, Yuan-Shan Branch, Yuan-Shan, Taiwan, R.O.C.
- Taiwan Ministry of Health and Welfare (MOHW), Taipei, Taiwan, R.O.C.
- Taiwan Ministry of Science and Technology (MOST), Taipei, Taiwan, R.O.C.
- Takeda Science Foundation, Japan
- Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan, R.O.C.
- Thailand Research Fund, Bangkok, Thailand
- Tissue Bank, China Medical University, Taichung, Taiwan, R.O.C.
- Tri-Service General Hospital Foundation, Taipei, Taiwan, R.O.C.
- University Nursing Program for Young Scholars with Creative Talents in Heilongjiang Province, P.R. China
- University of Antofagasta, Antofagasta, Chile
- University of California, Berkeley, CA, U.S.A.
- University of Minas Gerais, Belo Horizonte, Brazil
- University of Pernambuco, Pernambuco, Brazil
- University of Turin, Turin, Italy
- Victor Babes University of Medicine and Pharmacy Timisoara, Timisoara, Romania
- Wilhelm-Sander Foundation, München, Germany
- Wroclaw Medical University, Wroclaw, Poland
- Wroclaw University of Technology, Wroclaw, Poland
- Yakult Honsha Co., Ltd., Tokyo, Japan
- Yeditepe University, Istanbul, Turkey
- Yonsei University College of Medicine, Seoul, Republic of Korea

## Instructions for Authors 2020

**General Policy.** IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis; 10. Retrospective studies and case reports. The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to IN VIVO will be subject to peer-review, when appropriate, by two members of the Editorial Board. All manuscripts submitted to IN VIVO are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should take place under careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Such research should adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**Open Access Policy.** IN VIVO appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 700.00 (effective January 1, 2020) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. IN VIVO online will keep the volume and issue numbers, as well as page numbering.

**Copyright.** Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of IN VIVO articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in IN VIVO are the property of the publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear **at the end** of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are not subject to color charges.

**Tables.** All tables should appear **at the end** of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html). Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC -IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

**Ethical Policies and Standards.** IN VIVO agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### **Specific information and additional instructions for Authors**

1. In Vivo (IV) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.

3. Each manuscript submitted to IV is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to IV, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
4. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for IN VIVO:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to IN VIVO may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to IV.
  - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 59%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiaar-anticancer.org](mailto:journals@iiaar-anticancer.org).
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.  
(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of IV).